根据世界卫生组织临床和/或免疫学指南，对印度患者一线治疗失败时的C亚型1型人类免疫缺陷病毒分离株的逆转录酶序列进行分析。
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
作者信息
Deshpande Alaka, Jeannot Anne Cécile, Schrive Marie Hélène, Wittkop Linda, Pinson Patricia, Fleury Hervé J
机构信息
ART Center and Department of Internal Medicine, Sir JJ Hospital, Byculla, Mumbai, India.
出版信息
AIDS Res Hum Retroviruses. 2010 Mar;26(3):343-50. doi: 10.1089/aid.2009.0217.
The reverse transcriptase (RT) sequences of HIV-1 subtype C isolates from Indian patients at failure (according to WHO clinical or immunological criteria) of a first-line treatment including d4T/AZT-3TC-NVP/EFV were compared to those of HIV-1 isolates from naive patients and analyzed for drug resistance mutations (DRMs), which were interpreted according to ANRS and Stanford algorithms. All viruses were of subtype C. We have observed a decrease of the polymorphism at positions 36 and 214 of RT while D121Y, V179I, and Q217E could be new DRMs. Numerous crucial DRMs to NRTIs and NNRTIs could be recorded including TAMs of pathway 1 and K65R. According to both algorithms, the accumulation of DRMs may induce resistance to second-line NRTIs including tenofovir.
将一线治疗（包括司他夫定/齐多夫定-拉米夫定-奈韦拉平/依非韦伦）失败（根据世界卫生组织临床或免疫学标准）的印度患者中HIV-1 C亚型分离株的逆转录酶（RT）序列与初治患者的HIV-1分离株的序列进行比较，并分析耐药性突变（DRM），这些突变根据法国国家艾滋病研究机构（ANRS）和斯坦福算法进行解读。所有病毒均为C亚型。我们观察到RT第36和214位的多态性降低，而D121Y、V179I和Q217E可能是新的DRM。可以记录到许多对核苷类逆转录酶抑制剂（NRTI）和非核苷类逆转录酶抑制剂（NNRTI）至关重要的DRM，包括途径1的主要氨基酸变异（TAM）和K65R。根据这两种算法，DRM的积累可能导致对包括替诺福韦在内的二线NRTI产生耐药性。
Zotero 插件